Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 35-43

  Giovanella, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

18F fluorodeoxyglucose; differentiated thyroid carcinoma; iodine 124; positron emission tomography computed tomography; thyroid nodules

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 124; IODINE 131; THYROGLOBULIN;

ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; DOSIMETRY; ECHOGRAPHY; HUMAN; PREDICTION; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; TUMOR LOCALIZATION;

EID: 82955168311     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.83     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Tylski P, Stute S, Grotus N et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in 18F-FDG PET. J. Nucl. Med. 51, 268-276 (2010).
3. Czernin J, Schelbert H. PET/CT imaging: facts, opinions, hopes, and questions. J. Nucl. Med. 45, 1-3 (2004).
4. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin. Nucl. Med. 40, 283-293 (2010).
5. Koehler L, Gagnon K, McQuerrie S et al. Iodine-124: a promising positron emitter for organic PET chemistry. Molecules 15, 2686-2718 (2010).
6. Kloos RT. Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 93, 1519-1525 (2008).
7. Briele B, Hotze AL, Kropp J et al. A comparison of 201Tl and 99mtc-MIBI in the follow-up of differentiated thyroid carcinoma. Nuklearmedizin 30, 115-124 (1991).
8. Gorges R, Kahaly G, Muller-Brandt J et al. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in non-medullary thyroid cancer. Thyroid 11, 647-659 (2001).
9. Blaser D, Maschauer S, Kuwert T et al. In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-iodide. J. Nucl. Med. 47, 1382-1388 (2006).
10. Spitzweg C, Joba W, Morris JC et al. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thyroid cells. Thyroid 9, 821-830 (1999).
11. Russo D, Damante G, Foti D et al. Different molecular mechanisms are involved in the multihormonal control of glucose transport in FRTL5 rat thyroid cells. J. Endocrinol. Invest. 17, 323-327 (1994).
12. Grunwald F, Kalicke T, Feine U et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med. 26, 1547-1552 (1999).
13. Dietlein M, Scheidhauer K, Voth E et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. 24, 1342-1348 (1997).
14. Conti PS, Durski JM, Bacqai F et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9, 797-804 (1999).
15. Wang W, Macapinlac H, Larson SM et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J. Clin. Endocrinol. Metab. 84, 2291-2302 (1999).
16. Nahas Z, Goldenberg D, Fakhry C et al. The role of positron emission tomography/ computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115, 237-243 (2005).
17. Schluter B, Bohuslavizki KH, Beyer W et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med. 42, 71-76 (2001).
18. Alzahrani AS, Mohamed GE, Al Rifai A et al. Role of [18F] fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr. Pract. 12, 15215-15218 (2006).
19. Palmedo H, Bucerius J, Joe A et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J. Nucl. Med. 47, 616-624 (2006).
20. Finkelstein SE, Grigsby PW, Siegel BA et al. Combined [18F] Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann. Surg. Oncol. 15, 286-292 (2008).
21. Shammas A, Degirmenci B, Mountz JM et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well differentiated thyroid cancer. J. Nucl. Med. 48, 221-226 (2007).
22. Freudenberg LS, Frilling A, Kühl H et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur. Radiol. 1, 3139-3147 (2007).
23. Mirallié E, Guillan T, Bridji B et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 142, 952-958 (2007).
24. Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur. J. Radiol. 70, 17-24 (2008).
25. Iagaru A, Kalinyak, Mc Dougall IR. F-18 FDG PET/CT in the management of thyroid cancer. Clin. Nucl. Med. 32, 690-695 (2007).
26. Menzel C, Zaplatnikov K, Diehl M, Döbert N, Hamscho N, Grünwald F. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl. Med. Commun. 25, 239-243 (2004).
27. Cooper DS, Doherty GM, Haugen BR et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167-1214 (2009).
28. Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18FDG PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck doi:10.1002/hed.21791 (2011) (Epub ahead of print).
29. Vera P, Kuhn-Lansoy C, Edet-Sanson A et al. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D- glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Thyroid 2, 15-23 (2010).
30. Gharib H, Papini E, Paschke R et al. American association of clinical endocrinologists, associazione medici endocrinologi and European thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. AACE/ AME task force on thyroid nodules. Endocr. Pract. 16(Suppl. 1), S1-S43 (2010).
31. Chao M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin. Oncolol. (R. Coll. Radiol.). 22, 438-447 (2010).
32. Kim WG, Ryu JS, Kim EY et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable thyroglobulin but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomograph scan. J. Clin. Endocrinol. Metab. 95, 1169-1173 (2010).
33. Leboulleux S, Schroeder PR, Busaidy NL et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 94, 1310-1316 (2009).
34. Ma C, Xie J, Lou Y et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobluin and negative scan: a meta-analysis. Eur. J. Endocrinol. 163, 177-183 (2010).
35. Lazar V, Bidart JM, Caillou B et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab. 84, 3228-3234 (1999).
36. Wang W, Larson SM, Fazzari M et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endocrinol. Metab. 85, 1107-1113 (2000).
37. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J. Clin. Endocrinol. Metab. 91, 498-505 (2006).
38. Kraeber-Bodéré F, Cariou B, Curtet C et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery 138, 1176-1182 (2005).
39. Phan HTT, Jager PL, Paans AMJ et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 958-965 (2008).
40. Freudenberg LS, Antoch G, Frilling A et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/ CT and FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 35, 950-957 (2008).
41. Capoccetti F, Criscuoli B, Rossi G et al. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging 53, 536-545 (2009).
42. W Jentzen, L Freudenberg, EG Eising et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J. Nucl. Med. 49, 1017-1023 (2008).
43. Freudenberg LS, Frömke C, Petrich T et al. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer. Exp. Clin. Endocrinol. Diabet. 118, 393-399 (2010).